Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Am J Obstet Gynecol. 2017 Feb 7;216(5):529.e1–529.e8. doi: 10.1016/j.ajog.2017.01.040

Figure 7.

Figure 7

At buprenorphine trough, 36 week fetuses of women treated with higher buprenorphine dose (≥13 mg) presented with slower fetal heart rate, lower fetal heart rate variability, and approximately half the number of fetal heart rate accelerations as compared to fetuses of women treated with a lower dose.